Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) Income from Continuing Operations (2020 - 2024)

SELLAS Life Sciences (SLS) has disclosed Income from Continuing Operations for 8 consecutive years, with 6737000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Income from Continuing Operations rose 17.2% to 6737000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 30881000.0, a 18.16% increase, with the full-year FY2024 number at 30881000.0, up 17.31% from a year prior.
  • Income from Continuing Operations was 6737000.0 for Q4 2024 at SELLAS Life Sciences, up from 7108000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 2245000.0 in Q1 2021 to a low of 16735000.0 in Q1 2022.
  • A 5-year average of 7642050.0 and a median of 7308000.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 44.76% in 2021, then crashed 645.43% in 2022.
  • SELLAS Life Sciences' Income from Continuing Operations stood at 4159000.0 in 2020, then plummeted by 179.37% to 11619000.0 in 2021, then grew by 18.7% to 9446000.0 in 2022, then grew by 13.87% to 8136000.0 in 2023, then increased by 17.2% to 6737000.0 in 2024.
  • Per Business Quant, the three most recent readings for SLS's Income from Continuing Operations are 6737000.0 (Q4 2024), 7108000.0 (Q3 2024), and 7470000.0 (Q2 2024).